According to the listing prospectus, of the 16,371,959 registered shares entered in the Commercial Register, 5,400,000 or about 33 % of all outstanding shares were placed with the public. If the option for an additional 810,000 shares is chosen (over-allotment option), the free float may rise to 36.1 %. 5,400,000 of the placed shares proceed from a capital increase connected with the IPO.
Arpida is a biopharmaceutical company specialising in research into and development of new products for treating serious bacterial infections. The company has a fully integrated platform for discovering and developing medications for fighting bacteria that are becoming increasingly resistant to antibiotics. Arpida Ltd is domiciled in Münchenstein and employs 72 people.